ArticleThe Journal of infectious diseases2014
Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.
Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The Baboon as a Model to Study Human Health and Complex Disease.American journal of primatology · 2026Review
- Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations.NPJ vaccines · 2026Article
- Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine.NPJ vaccines · 2025Article
- Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in Africa.Scientific reports · 2025Article
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine.NPJ vaccines · 2025Article
- From cercariae to chronic inflammation: understanding schistosome infection and host immune responses.Frontiers in immunology · 2025Review
- An assessment of a GMP schistosomiasis vaccine (SchistoShieldFrontiers in tropical diseases · 2024Article
- Schistosomiasis.Advances in experimental medicine and biology · 2024Review
- Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice.NPJ vaccines · 2023Article
- Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.Frontiers in tropical diseases · 2021Article
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Application of Schistosomiasis Consortium for Operational Research and Evaluation Study Findings to Refine Predictive Modeling ofThe American journal of tropical medicine and hygiene · 2020Review
- Schistosomiasis-from immunopathology to vaccines.Seminars in immunopathology · 2020Review
- Schistosomiasis vaccine development: update on human clinical trials.Journal of biomedical science · 2020Review
- Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer ProtectionFrontiers in immunology · 2020Article
- Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development.Research and reports in tropical medicine · 2020Review
- Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison.Parasites & vectors · 2019Article
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2018Article
- Correlates of GLA family adjuvants' activities.Seminars in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
No vaccines are available for human use for any parasitic infections, including the helminthic disease schistosomiasis. Sm-p80, the large subunit of Schistosoma mansoni calpain, is a leading antigen candidate for a schistosomiasis vaccine. Prophylactic and antifecundity efficacies of Sm-p80 have been tested using a variety of vaccine approaches in both rodent and nonhuman primate models. However, the therapeutic efficacy of a Sm-p80-based vaccine had not been determined. In this study, we evaluated the therapeutic efficacy of Sm-p80 by using 2 different strategies and 3 Sm-p80-based vaccine formulations in baboons. Vaccine formulations were able to decrease established adult worms by 10%-36%, reduce retention of eggs in tissues by 10%-57%, and decrease egg excretion in feces by 13%-33%, compared with control formulations. Marked differences were observed in B and T cell immune correlates between vaccinated and control animals. This is the first report of killing of established adult schistosome worms by a vaccine. In addition to distinct prophylactic efficacy of Sm-p80, this study adds to the evidence that Sm-p80 is a potentially important antigen with both substantial prophylactic and therapeutic efficacies. These data reinforce that Sm-p80 should be moved forward along the path toward human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.